Indobufen Dual Antiplatelet Therapy (DAPT) Versus Aspirin Dual Antiplatelet Therapy (DAPT) After Percutaneous Coronary Intervention (PCI): A Systematic Review and Meta‐Analysis
Catheterization and Cardiovascular Interventions · 2026-03 · 107 (4) · 1225-1236
DOI: 10.1002/ccd.70463 ↗At a glance
Systematische Übersicht in Catheterization and Cardiovascular Interventions, published online on 2026-01-07. Written by Omar Saeed and 8 co-authors. Institution: Faculty of Medicine, Al-Azhar University, Damietta, Egypt. Major MEDLINE topics: Percutaneous Coronary Intervention, Aspirin, Platelet Aggregation Inhibitors, Dual Anti-Platelet Therapy. Cited 1 times so far (Crossref); 32 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
Background
Dual antiplatelet therapy (DAPT), which combines aspirin with a P2Y12 receptor inhibitor, is considered the standard of care for patients who have had percutaneous coronary intervention (PCI). This study aimed to compare indobufen‐based (DAPT) to aspirin‐based (DAPT) after PCI.
Methods
This systematic review and meta‐analysis analyzed randomized controlled trials (RCTs) and propensity‐matched cohort studies comparing indobufen (DAPT) to standard aspirin (DAPT) after PCI. We searched four databases: PubMed, Scopus, Web of Science, and Cochrane through January 2025 and updated the search in September 2025. Dichotomous data were pooled as odds ratios with 95% CIs.
Results
Our search identified 403 records; only five studies were included in the analysis. Comparing major adverse cardiac and cerebrovascular events (MACCE) between the indobufen and aspirin groups, no difference was observed (OR 1.12, 95% CI: 0.87–1.46; p = 0.38). Bleeding BARC types 2, 3, 5 were compared between the two groups, showing fewer bleeding events in the indobufen group than in the aspirin group (OR: 0.47, 95% CI: 0.24–0.95; p = 0.03).
Conclusion
Indobufen‐based (DAPT) had a lower incidence of bleeding than aspirin‐based (DAPT), with no difference between the two groups for MACCE, myocardial infarction, ischemic stroke, cardiovascular death, repeat vascularization, or stent thrombosis.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Faculty of Medicine, Al-Azhar University, Damietta, Egypt.
- Faculty of Medicine, University of Aleppo, Aleppo, Syria.
- College of Medicine (HUCOM), Hadhramout University, Hadhramout, Yemen.
- İstinye Üniversitesi, İstanbul, Turkey.
- Faculty of Medicine, University of Gezira, Wad Madani, Sudan.
- Faculty of Medicine, Sabha University, Sabha, Libya.
ORCID profiles: Muhammed Elhadi, Mamas A Mamas
Cite
APA
Saeed, O., Saeed, A., Barakat, O., Bawjeh, A., Saka, T., Yousif, T. M., Adim, A. M., Elhadi, M., & Mamas, M. A. (2026). Indobufen Dual Antiplatelet Therapy (DAPT) Versus Aspirin Dual Antiplatelet Therapy (DAPT) After Percutaneous Coronary Intervention (PCI): A Systematic Review and Meta‐Analysis. Catheterization and Cardiovascular Interventions, 107(4), 1225-1236. https://doi.org/10.1002/ccd.70463
Vancouver
Saeed O, Saeed A, Barakat O, Bawjeh A, Saka T, Yousif TM, et al. Indobufen Dual Antiplatelet Therapy (DAPT) Versus Aspirin Dual Antiplatelet Therapy (DAPT) After Percutaneous Coronary Intervention (PCI): A Systematic Review and Meta‐Analysis. Catheterization and Cardiovascular Interventions. 2026;107(4):1225-1236. doi:10.1002/ccd.70463
BibTeX
@article{Saeed2026,
author = {Saeed, Omar and Saeed, Abdelrahman and Barakat, Osama and Bawjeh, Abdulaziz and Saka, Tuğba and Yousif, Tasneem Mustafa and Adim, Aeshah Mohammed and Elhadi, Muhammed and Mamas, Mamas A},
title = {Indobufen Dual Antiplatelet Therapy (DAPT) Versus Aspirin Dual Antiplatelet Therapy (DAPT) After Percutaneous Coronary Intervention (PCI): A Systematic Review and Meta‐Analysis},
journal = {Catheterization and Cardiovascular Interventions},
year = {2026},
volume = {107},
number = {4},
pages = {1225--1236},
doi = {10.1002/ccd.70463}
}
EUVIMED